For opioid and stimulant dependence, ibogaine has clearer direct evidence. Studies show it eliminates or drastically reduces acute withdrawal symptoms in approximately 80% of participants, with 30 to 50% achieving short-term opioid cessation (Davis et al., 2017; Mash et al., 2018; Noller et al., 2018). Ayahuasca has stronger evidence for alcohol and tobacco reduction and for the emotional healing that supports long-term recovery. For someone in active opioid withdrawal, ibogaine is the more appropriate first intervention. Ayahuasca may be more valuable in the integration phase that follows.